The pharmacokinetics of zileuton in healthy young and elderly volunteers.

abstract：:Although activity of cytochrome P450 isoenzymes (CYPs) plays a major role in the fate of anticancer agents in patients, there are relatively few clinical studies that evaluate drug metabolism with therapeutic outcome. Nevertheless, many clinical reports in various non-oncology fields have shown the dramatic importance...

journal_title：Clinical pharmacokinetics

authors： Rochat B

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Fat-free mass (FFM)-based dose scaling is increasingly being adopted in clinical pharmacology. Given the complexities with the measurement of FFM in clinical practice, choosing an appropriate equation for FFM is critical for accurate dose scaling. Janmahasatian's FFM model (FFMJan) has largely remained the p...

journal_title：Clinical pharmacokinetics

authors： Sinha J,Al-Sallami HS,Duffull SB

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:The imatinib trough plasma concentration (C(min)) correlates with clinical response in cancer patients. Therapeutic drug monitoring (TDM) of plasma C(min) is therefore suggested. In practice, however, blood sampling for TDM is often not performed at trough. The corresponding measurement is thus only remotely...

journal_title：Clinical pharmacokinetics

authors： Gotta V,Widmer N,Montemurro M,Leyvraz S,Haouala A,Decosterd LA,Csajka C,Buclin T

更新日期：2012-03-01 00:00:00

abstract：:Drug-drug, drug-formulation and drug-meal interactions are of clinical concern for orally administered drugs that possess a narrow therapeutic index. This review presents the current status of information regarding interactions which may influence the gastrointestinal (GI) absorption of orally administered drugs. Abso...

journal_title：Clinical pharmacokinetics

authors： Fleisher D,Li C,Zhou Y,Pao LH,Karim A

更新日期：1999-03-01 00:00:00

abstract：:Various pharmacokinetic models, both simple and complex, have been developed to describe the way in which the rate of hepatic elimination of drugs depends on hepatic blood flow, hepatic intrinsic clearance and unbound fraction of drug in blood. A model is necessary because it is not possible to measure the average blo...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,Smallwood RA

更新日期：1990-01-01 00:00:00

abstract：:Lignocaine is widely used as a local anaesthetic and antiarrhythmic drug. It is commonly administered to patients with acute myocardial infarction as prophylaxis for ventricular fibrillation, although its efficacy in preventing primary ventricular fibrillation is still debated. Toxicity, sometimes with serious clinica...

journal_title：Clinical pharmacokinetics

authors： Benowitz NL,Meister W

更新日期：1978-05-01 00:00:00

abstract：:According to recent clinical consensus, pharmacotherapy of inflammatory bowel disease (IBD) is, or should be, personalized medicine. IBD treatment is complex, with highly different treatment classes and relatively few data on treatment strategy. Although thorough evidence-based international IBD guidelines currently e...

journal_title：Clinical pharmacokinetics

authors： Derijks LJJ,Wong DR,Hommes DW,van Bodegraven AA

更新日期：2018-09-01 00:00:00

abstract：:In the original publication, Page 3, Sect. 4.3, the first sentence was incorrectly published. ...

journal_title：Clinical pharmacokinetics

authors： Martin JH,Schneider J,Lucas CJ,Galettis P

更新日期：2018-05-01 00:00:00

abstract：:There is a considerable range in the dose of many drugs that is required to produce a given pharmacological effect in an individual patient. This individual variation in dose requirement is sometimes reflected in the wide scatter in the steady state plasma concentration that follows the same oral dose of a drug given ...

journal_title：Clinical pharmacokinetics

authors： Parsons RL

更新日期：1977-01-01 00:00:00

abstract：:For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information. However, now that this information is available, it is appropriate to examine current recommendations for prophylaxis and treatment. In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine an...

journal_title：Clinical pharmacokinetics

authors： White NJ

更新日期：1985-05-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:This study proposes a model-informed approach for therapeutic drug monitoring (TDM) of rifampicin to improve tuberculosis (TB) treatment. METHODS:Two datasets from pulmonary TB patients were used: a pharmacokinetic study (34 patients, 373 samples), and TDM data (96 patients, 391 samples) colle...

journal_title：Clinical pharmacokinetics

authors： van Beek SW,Ter Heine R,Keizer RJ,Magis-Escurra C,Aarnoutse RE,Svensson EM

更新日期：2019-06-01 00:00:00

abstract：:Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and rea...

journal_title：Clinical pharmacokinetics

authors： Rao N

更新日期：2007-01-01 00:00:00

abstract：:Bioequivalence of drug formulations plays an important role in drug development. Recently, the Biopharmaceutical Classification System (BCS) has been implemented for the purpose of waiving bioequivalence studies on the basis of the solubility and gastrointestinal permeability of drug substance. Using the rationale of ...

journal_title：Clinical pharmacokinetics

authors： Faassen F,Vromans H

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Reducing the dose of efavirenz can improve safety, reduce costs, and increase access for patients with HIV infection. According to the World Health Organization, a similar dosing strategy for all patient populations is desirable for universal roll-out; however, it remains unknown whether the 400 mg daily dos...

journal_title：Clinical pharmacokinetics

authors： Schalkwijk S,Ter Heine R,Colbers AC,Huitema ADR,Denti P,Dooley KE,Capparelli E,Best BM,Cressey TR,Greupink R,Russel FGM,Mirochnick M,Burger DM

更新日期：2018-11-01 00:00:00

abstract：:Rapid drug delivery (arterial "boli') and high drug concentrations occur with nicotine inhaled in smoke. These are believed to be key elements in producing addiction to cigarettes. Preparations which reduce the rate of delivery and/or concentration of nicotine have been introduced as treatments for smoking cessation. ...

journal_title：Clinical pharmacokinetics

authors： Schneider NG,Lunell E,Olmstead RE,Fagerström KO

更新日期：1996-07-01 00:00:00

abstract：:The pharmacokinetics and antihypertensive effects of felodipine, a new dihydropyridine calcium channel blocker, were studied in elderly hypertensive patients, 67 to 79 years of age and in young healthy subjects, 20 to 34 years of age following oral administration of 5 mg twice daily to steady-state. A single intraveno...

journal_title：Clinical pharmacokinetics

authors： Landahl S,Edgar B,Gabrielsson M,Larsson M,Lernfelt B,Lundborg P,Regårdh CG

更新日期：1988-06-01 00:00:00

abstract：:This article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P450 (CYP) isoform(s) metabolising a particu...

journal_title：Clinical pharmacokinetics

authors： Bertz RJ,Granneman GR

更新日期：1997-03-01 00:00:00

abstract：:The ability to deliver safe and effective moderate sedation is crucial to the ability to perform invasive procedures. Sedative drugs should have a quick onset of action, provide rapid and clear-headed recovery, and be easy to administer and monitor. A number of drugs have been demonstrated to provide effective sedatio...

journal_title：Clinical pharmacokinetics

authors： Gan TJ

更新日期：2006-01-01 00:00:00

abstract：:Dilevalol and labetalol are examples of a growing number of new beta-blockers which combine nonselective beta-adrenoceptor antagonism with vasodilator activity. Dilevalol is one of the 4 stereoisomers of labetalol, and is estimated to form approximately 25% of the racemic drug. Labetalol itself is an alpha 1-antagonis...

journal_title：Clinical pharmacokinetics

authors： Donnelly R,Macphee GJ

更新日期：1991-08-01 00:00:00

abstract：:With the aging population and its rapidly increasing prevalence, dementia has become an important public health concern in developed and developing countries. To date, the pharmacological treatment is symptomatic and based on the observed neurotransmitter disturbances. The four most commonly used drugs are donepezil, ...

journal_title：Clinical pharmacokinetics

authors： Noetzli M,Eap CB

更新日期：2013-04-01 00:00:00

abstract：:Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor (VEGF), platelet-de...

journal_title：Clinical pharmacokinetics

authors： Wind S,Schmid U,Freiwald M,Marzin K,Lotz R,Ebner T,Stopfer P,Dallinger C

更新日期：2019-09-01 00:00:00

abstract：:The treatment of epilepsy in pregnancy is particularly challenging in that the fetal and maternal risks associated with maternal seizures need to be balanced against the potential teratogenic effects of antiepileptic drugs (AEDs). Pregnancy is known to affect the pharmacokinetics of older-generation AEDs. Understandin...

journal_title：Clinical pharmacokinetics

authors： Tomson T,Battino D

更新日期：2007-01-01 00:00:00

abstract：:Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin...

journal_title：Clinical pharmacokinetics

authors： Scheen AJ

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:From a previously validated paediatric population pharmacokinetic model, it was derived that non-linear morphine maintenance doses of 5 μg/kg(1.5)/h, with a 50 % dose reduction in neonates with a postnatal age (PNA) <10 days, yield similar morphine and metabolite concentrations across patients...

journal_title：Clinical pharmacokinetics

authors： Krekels EH,Tibboel D,de Wildt SN,Ceelie I,Dahan A,van Dijk M,Danhof M,Knibbe CA

更新日期：2014-06-01 00:00:00

abstract：:The combination of artemether and lumefantrine (benflumetol) is a new and very well tolerated oral antimalarial drug effective even against multidrug-resistant falciparum malaria. The artemether component is absorbed rapidly and biotransformed to dihydroartemisinin, and both are eliminated with terminal half-lives of ...

journal_title：Clinical pharmacokinetics

authors： White NJ,van Vugt M,Ezzet F

更新日期：1999-08-01 00:00:00

abstract：BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

journal_title：Clinical pharmacokinetics

authors： Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

更新日期：2016-12-01 00:00:00

abstract：:A substantial proportion of migraine patients have gastric stasis and suffer severe nausea and/or vomiting during their migraine attack. This may lead to erratic absorption from the gastrointestinal tract and make oral treatment unsatisfactory. For such patients, an intranasal formulation may be advantageous. Sumatrip...

journal_title：Clinical pharmacokinetics

authors： Fuseau E,Petricoul O,Moore KH,Barrow A,Ibbotson T

更新日期：2002-01-01 00:00:00

abstract：:High dosage busulfan (1 mg/kg orally every 6 hours x 16 doses) is frequently used in preparative regimens for haemopoietic stem cell transplantation (HSCT). Busulfan is well absorbed after oral administration, exhibits low protein binding and is metabolised through conjugation with glutathione to form a thiophenium io...

journal_title：Clinical pharmacokinetics

authors： McCune JS,Gibbs JP,Slattery JT

更新日期：2000-08-01 00:00:00

abstract：:The plasma protein binding of drugs, particularly those that are highly bound, may have significant clinical implications. Although protein binding is a major determinant of drug action, it is only one of a myriad of factors that influence drug disposition. The extent of protein binding is a function of drug and prote...

journal_title：Clinical pharmacokinetics

authors： Grandison MK,Boudinot FD

更新日期：2000-03-01 00:00:00

abstract：:Consistent with its highest abundance in humans, cytochrome P450 (CYP) 3A is responsible for the metabolism of about 60% of currently known drugs. However, this unusual low substrate specificity also makes CYP3A4 susceptible to reversible or irreversible inhibition by a variety of drugs. Mechanism-based inhibition of ...

journal_title：Clinical pharmacokinetics

authors： Zhou S,Yung Chan S,Cher Goh B,Chan E,Duan W,Huang M,McLeod HL

更新日期：2005-01-01 00:00:00